Ethermed | $8,500,000 | (Apr 17, 2026)
Joyful Health | $17,000,000 | (Apr 17, 2026)
Worki.ai | $2,750,000 | (Apr 17, 2026)
Helex
United States
- New York, NY
- 04/11/2025
- Seed
- $3,500,000
Helex is taking the promise of non-viral targeted delivery and genome editing to the kidney, developing first-in-class genetic medicines for renal indications. Helex combines its proprietary kidney tropic lipid nanoparticle delivery system with the Epic-Cure(TM) 3D genome-based drug designer platform to create a robust renal franchise of precise and scalable therapeutics. Our lead asset is a mutation-agnostic, potential one-and-done therapy for Autosomal Dominant Polycystic Kidney Disease that impacts over 4 million people worldwide.
- Industry Biotechnology
- Website https://www.helex.bio/
- LinkedIn https://www.linkedin.com/company/helexbio/
Related People
Dr Poulami ChaudhuriFounder
India -
ND
I bring over a decade of experience in lipid nanoparticle-based delivery, peptide-based delivery, and molecular biology, with a focus on advancing genomic medicines. I completed my PhD and MSc at King’s College London, where my research focused on non-viral delivery systems for therapeutic applications, including the development of peptide-based vectors for siRNA delivery in cancer treatments.
During my postdoctoral work at TCS Innovation Labs, I explored 3D genome architecture and epigenetics in human cells, which laid the foundation for my leadership in developing the EPIC-Cure™ drug design platform at Helex. As Lead Scientist at TCS Innovation Labs, I led critical research on genetic diseases like Duchenne Muscular Dystrophy (DMD), which contributed to the development of several patents.
At Helex, I have been driving the development of innovative lipid nanoparticle (LNP) and drug design platforms, securing numerous patents for novel lipids, LNPs, and gene-editing technologies. I’m deeply committed to advancing cutting-edge delivery platforms that tackle high-burden diseases and transform the landscape of genomic medicines by making them accessible to patients worldwide.
Balerion AI | $6,000,000 | (Apr 17, 2026)
Beeline Medicines | $300,000,000 | (Apr 17, 2026)
Expo | $45,000,000 | (Apr 17, 2026)
Sepion Technologies | $10,000,000 | (Apr 17, 2026)
Lua AI (YC F25) | $5,800,000 | (Apr 17, 2026)
Nas.com | $27,000,000 | (Apr 17, 2026)
Resolv | $1,000,000 | (Apr 17, 2026)
Solidroad | $25,000,000 | (Apr 17, 2026)
Parasail | $32,000,000 | (Apr 16, 2026)